Biofrontera Inc.
BFRI
$1.54
-$0.02-1.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 17.83% | 13.70% | 11.75% | 5.11% | 11.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.83% | 13.70% | 11.75% | 5.11% | 11.20% |
| Cost of Revenue | -40.34% | -44.75% | -41.08% | -29.28% | -12.80% |
| Gross Profit | 58.21% | 64.98% | 64.26% | 43.72% | 37.46% |
| SG&A Expenses | 10.80% | 22.42% | 13.40% | 9.12% | 2.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.66% | -0.66% | -2.72% | 0.11% | 2.63% |
| Operating Income | 62.14% | 34.16% | 34.08% | 9.02% | 13.41% |
| Income Before Tax | 61.77% | 3.89% | 40.75% | -36.90% | -22.81% |
| Income Tax Expenses | 45.00% | 42.11% | 23.81% | 27.78% | 25.00% |
| Earnings from Continuing Operations | 61.64% | 3.82% | 40.67% | -36.89% | -22.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.64% | 3.82% | 40.67% | -36.89% | -22.81% |
| EBIT | 62.14% | 34.16% | 34.08% | 9.02% | 13.41% |
| EBITDA | 62.89% | 33.86% | 33.25% | 7.13% | 12.20% |
| EPS Basic | 73.43% | 34.36% | 71.29% | 18.58% | 62.70% |
| Normalized Basic EPS | 70.79% | 30.67% | 69.17% | 65.37% | 69.41% |
| EPS Diluted | 73.43% | 34.36% | 71.29% | 18.58% | 62.70% |
| Normalized Diluted EPS | 70.79% | 30.67% | 69.17% | 65.37% | 69.41% |
| Average Basic Shares Outstanding | 49.05% | 59.22% | 84.39% | 119.90% | 158.26% |
| Average Diluted Shares Outstanding | 49.05% | 59.22% | 84.39% | 119.90% | 158.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |